Literature DB >> 8702532

Suppression of syndecan-1 expression in endothelial cells by tumor necrosis factor-alpha.

V Kainulainen1, L Nelimarkka, H Järveläinen, M Laato, M Jalkanen, K Elenius.   

Abstract

Syndecan-1 is a cell surface proteoglycan that binds extracellular matrix components and modulates the activity of heparin-binding growth factors. The expression of syndecan-1 is modified during development, carcinogenesis, and tissue regeneration. During cutaneous wound healing, syndecan-1 expression is transiently induced in newly-formed capillaries of granulation tissue as well as in proliferating keratinocytes. To study the mechanisms underlying this regulation we investigated the effects of several growth factors/cytokines on syndecan-1 expression in two human cell lines: EA.hy 926 endothelial cells and HaCaT keratinocytes. None of these factors significantly altered syndecan-1 mRNA expression in cultured keratinocytes, but when given to endothelial cells, tumor necrosis factor-alpha (TNF-alpha) specifically and dose-dependently suppressed syndecan-1 expression at both mRNA and protein levels. TNF-alpha reduced the amount of syndecan-1 protein in EA.hy 926 cells in both the presence and absence of serum and, at the same time, induced the expression of intercellular adhesion molecule-1 (ICAM-1). The suppressive effect of TNF-alpha on endothelial syndecan-1 expression was reproducible in in vivo experiments in which TNF-alpha-coated beads were administered directly to healing skin wounds of mice. Data supporting these findings were further obtained by injecting TNF-alpha into an experimental rat granulation tissue model. In this tissue TNF-alpha suppressed syndecan-1 mRNA expression by approximately 80%. These results indicate that TNF-alpha is capable of down-regulating syndecan-1 expression in endothelial cells both in vitro and in vivo and suggest that similar mechanisms may be responsible for the changes in syndecan-1 expression observed during various regenerative, developmental, and malignant processes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702532     DOI: 10.1074/jbc.271.31.18759

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy.

Authors:  R Day; M Ilyas; P Daszak; I Talbot; A Forbes
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

2.  Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2010-11-01       Impact factor: 5.285

Review 3.  Polyunsaturated fatty acid metabolism in prostate cancer.

Authors:  Isabelle M Berquin; Iris J Edwards; Steven J Kridel; Yong Q Chen
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 5.  Syndecans: multifunctional cell-surface co-receptors.

Authors:  D J Carey
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

Review 6.  Syndecans in cartilage breakdown and synovial inflammation.

Authors:  Thomas Pap; Jessica Bertrand
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

7.  Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5.

Authors:  Kazutaka Hayashida; Philip D Stahl; Pyong Woo Park
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

8.  A low molecular weight heparin inhibits experimental metastasis in mice independently of the endothelial glycocalyx.

Authors:  Geerte L Van Sluis; Max Nieuwdorp; Pieter W Kamphuisen; Johan van der Vlag; Cornelis J F Van Noorden; C Arnold Spek
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

9.  Syndecan-1 - A new piece in B-cell puzzle.

Authors:  L Kopper; A Sebestyén; M Gallai; I Kovalszky
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

10.  Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity.

Authors:  Christian H Schweppe; Martina Bielaszewska; Gottfried Pohlentz; Alexander W Friedrich; Heino Büntemeyer; M Alexander Schmidt; Kwang S Kim; Jasna Peter-Katalinić; Helge Karch; Johannes Müthing
Journal:  Glycoconj J       Date:  2008-01-05       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.